The disclosure provides topical pharmaceutical compositions comprising a macrolide immunosuppressant, e.g., selected from pimecrolimus, sirolimus, and tacrolimus, optionally in combination with efinaconazole, as well as the use of such compositions to treat inflammatory skin conditions.
Mergers and Acquisitions Securities and Capital Markets Venture Capital and Private Equity Securities Debt and Equity Securities Offerings Private Equity Private M&A Public M&A
ISLN:
908413698
Admitted:
1984
University:
The University of Hong Kong, 1981
Law School:
London School of Economics and Political Science, LL.M., 1982; The University of Hong Kong, LL.B., 1980